The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The influence of TP53 mutations in MDS with isolated 5q deletion
In this video, Maria Julia Montoro, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, briefly comments on the influence of TP53 gene mutations in patients with myelodysplastic syndrome (MDS) with isolated 5q deletion (del5q). In a study by Dr Montoro, multi-hit TP53 mutations did not impact overall survival (OS). However, patients with TP53 mutations demonstrated an increased risk of progression to acute myeloid leukemia (AML). This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
As the TP53 multi-hit mutations have been correlated with worse prognosis in the overall population of MDS, we wonder if this worst prognostic impact is also in MDS-del5q, which I also mentioned, these patients present really good outcomes. So we did this study in this cohort of patients and we found that these multi-hit mutations didn’t impact on the overall survival...
As the TP53 multi-hit mutations have been correlated with worse prognosis in the overall population of MDS, we wonder if this worst prognostic impact is also in MDS-del5q, which I also mentioned, these patients present really good outcomes. So we did this study in this cohort of patients and we found that these multi-hit mutations didn’t impact on the overall survival. However, those patients with TP53 mutations really increased the risk of progression to acute myeloid leukemia. So that was the main finding of our first study with these patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
